AstraZeneca divests rights to established hypertension medicines

Click here to view online. Add this email to your safelist.

27 January 2020

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs).

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.